Back to top
more

Kura Oncology (KURA)

(Real Time Quote from BATS)

$8.85 USD

8.85
89,337

+0.06 (0.68%)

Updated Apr 9, 2026 11:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Implied Volatility Surging for Kura Oncology Stock Options

by Zacks Equity Research

Investors need to pay close attention to Kura Oncology stock based on the movements in the options market lately.

Zacks Equity Research

Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kura Oncology (KURA) delivered earnings and revenue surprises of -28.67% and -41.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

by Zacks Equity Research

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline

by Zacks Equity Research

Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for January 21st

by Zacks Equity Research

CRNT, KURA and CLSDQ have been added to the Zacks Rank #5 (Strong Sell) List on January 21, 2026.

Zacks Equity Research

Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kura Oncology (KURA) delivered earnings and revenue surprises of -49.12% and -75.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Kura Oncology Stock?

by Zacks Equity Research

Investors need to pay close attention to KURA stock based on the movements in the options market lately.

Zacks Equity Research

KURA Stock Rises More Than 15% This Past Week: Here's Why

by Zacks Equity Research

Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.

Zacks Equity Research

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kura Oncology (KURA) delivered earnings and revenue surprises of -29.41% and 88.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?